Results 101 to 110 of about 71,336,553 (298)

IL3RA (interleukin-3 receptor alpha) [PDF]

, 2005
Review on IL3RA (interleukin-3 receptor alpha), with data on DNA, on the protein encoded, and where the gene is ...
Testa, U
core   +1 more source

Cerebrospinal Fluid Over Plasma Links Analytes to Cognitive Decline in Older Adults at Risk for Alzheimer's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify inflammatory analytes in cerebrospinal fluid (CSF) and plasma associated with cognitive decline in cognitively normal (CN) older adults at risk for Alzheimer's disease (AD). Methods In a longitudinal study of 118 CN older adults (65–80 years, 54% APOE ε4, 26% preclinical AD), 1331 CSF and 1501 plasma analytes were ...
Jagan A. Pillai, Audrey Zhu, Chunxuan Ma, Ming Wang, Yifan Yang, Lynn M. Bekris, Maria Khrestian, Frank P. DiFilippo, Mikhail Nasrallah, Aaron Burberry, James B. Leverenz, Yuan Hou, Feixiong Cheng, Stephen M. Rao   +13 more
wiley   +1 more source

In Vivo Dioxin Favors Interleukin-22 Production by Human CD4+ T Cells in an Aryl Hydrocarbon Receptor (AhR)-Dependent Manner

PLoS ONE, 2011
The transcription factor aryl hydrocarbon receptor (AhR) mediates the effects of a group of chemicals known as dioxins, ubiquitously present in our environment. However, it is poorly known how the in vivo exposure to these chemicals affects in humans the adaptive immune response.
Brembilla, Nicolò Costantino, Ramirez, Jean-Marie, Chicheportiche, Rachel, Sorg, Olivier, Saurat, Jean-Hilaire, Chizzolini, Carlo   +5 more
openaire   +8 more sources

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Dysregulated Cholesterol Metabolism, Chronic Inflammation, and Disability in Severe Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Dysregulated lipid metabolism, which can affect remyelination and neural repair, has not been extensively investigated in progressive multiple sclerosis (PMS). The goal was to examine whether dysregulated cholesterol metabolism was associated with disability in PMS. Methods The study sample comprised 53 Severe PMS patients (Expanded
Taylor R. Wicks, Mujeeb Shittu, Anna Wolska, Diala Ghazal, Bianca Weinstock‐Guttman, Alexander Burnham, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +8 more
wiley   +1 more source

Soluble interleukin 2 receptor levels.

, 2019
Soluble interleukin 2 receptor levels.
Jelle R. Miedema (7512251), Willem A. Dik (5871578), Paul L. A. van Daele (6398810), Laura E. M. Eurelings (7512248), P. Martin van Hagen (7329032), Jan A. M. van Laar (3145434), Virgil A. S. H. Dalm (6004133)   +6 more
core   +1 more source

Alternate transcription of the Toll-like receptor signaling cascade [PDF]

, 2006
Alternate splicing of key signaling molecules in the Toll-like receptor (Tlr) cascade has been shown to dramatically alter the signaling capacity of inflammatory cells, but it is not known how common this mechanism is. We provide transcriptional evidence
Kai, Chikatoshi, Forrest, A, Schroder, K, Forrest, Alistair, Kawai, J, Kawaji, H, Wells, Christine A, Faulkner, G, Carninci, P, Hume, DA, Carninci, Piero, Grimmond, SM, Himes, SR, Lo, Sandra, Schroder, Kate, Taylor, D, Grimmond, Sean M, Faulkner, Geoffrey, Kasukawa, T, Himes, S Roy, Kawai, Jun, Waddell, Nic, Hayashizaki, Yoshihide, Kasukawa, Takeya, Katayama, S, Hayashizaki, Y, Chalk, Alistair M, Katayama, Shintaro, Hume, David A, Chalk, AM, Taylor, Darrin, Kawaji, Hideya, Wells, CA, Waddell, N, Lo, S, Kai, C   +35 more
core   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis [PDF]

, 2012
Idiopathic pulmonary fibrosis (IPF) is a fatal disease that is unresponsive to current therapies and characterized by excessive collagen deposition and subsequent fibrosis.
Bozinovski, S, O'Donoghue, R.J.J., Prêle, C.M., Ernst, M.R., Anderson, GP, Vlahos, R., Knight, DA, McKenzie, B.S., Wang, B, Jarnicki, AG, Prêle, CM, Laurent, GJ, McAnulty, R.J., Thiem, S, Lau, HL, Vlahos, R, Zhu, H.J., Richards, CD, Mutsaers, SE, Ernst, MR, Stumbles, P.A., Laurent, G.J., Knight, D.A., Thiem, S., Jarnicki, A.G., Lau, H.L., O'Donoghue, RJJ, McAnulty, RJ, Stumbles, P, Richards, C.D., Anderson, G.P., McKenzie, BS, Rose-John, S, Mutsaers, S.E., Zhu, HJ, Wang, B., Jones, J., Rose-John, S., Jones, J, Bozinovski, S.   +39 more
core   +1 more source

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

Arthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source